According to the agreement, Twist Biopharma, a division of Twist, will use its panel of synthetic antibody phage display libraries derived from human sequences to identify potential therapeutic antibody candidates. Twist and Boehringer will work together to validate and optimize any resulting new antibody candidates for use in multiple therapeutic areas.

Twist will receive an upfront payment for each program entry, and the company could potentially earn up to $710 million in success-based clinical, regulatory, and commercial milestone payments for the multiple target discovery programs.

Twist reports revenue increases for Q3
Twist Bioscience reported revenue increases for the third quarter of fiscal 2021, which ended June 30.

Twist incorporates Molcure AI into antibody discovery efforts
Twist Bioscience announced that it has used Molcure's artificial intelligence (AI) technology to generate new cancer antibodies.

Twist acquires iGenomX for $35M
Twist Bioscience has acquired next-generation sequencing library preparation developer iGenomX for $35 million. The deal gives Twist a leg up in...

Boehringer Ingelheim, Lifebit partner on AI for infectious disease outbreaks
Boehringer Ingelheim has established a long-term partnership with Lifebit Biotech to utilize natural language processing and artificial intelligence (AI)...

Boehringer Ingelheim to advance Dicerna RNAi candidate
Boehringer Ingelheim has accepted Dicerna Pharmaceuticals GalXC RNA interference (RNAi) candidate for its development for the treatment of chronic liver...

Boehringer Ingelheim, Cure Genetics to develop novel AAV
Cure Genetics will collaborate with Boehringer Ingelheim to develop novel adeno-associated virus (AAV) vectors leveraging Cure Genetics' proprietary Velp...